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Long-term non-progressors (LTNP) were identified after 10–15 years of the epidemic, and
have been the subject of intense investigation ever since. In a small minority of cases,
infection with nef/3′LTR deleted attenuated viral strains allowed control over viral replica-
tion. A common feature of LTNP is the readily detected proliferation of CD4T-cells in vitro, in
response to p24. In some cases, the responding CD4T-cells have cytotoxic effector function
and may target conserved p24 epitopes, similar to the CD8 T-cells described below. LTNP
may also carry much lower HIV DNA burden in key CD4 subsets, presumably resulting from
lower viral replication during primary infection. Some studies, but not others, suggest that
LTNP have CD4 T-cells that are relatively resistant to HIV infection in vitro. One possible
mechanism may involve up-regulation of the cell cycle regulator p21/waf in CD4T-cells from
LTNP. Delayed progression in Caucasian LTNP is also partly associated with heterozygos-
ity of the ∆32 CCR5 allele, probably through decreased expression of CCR5 co-receptor
on CD4 T-cells. However, in approximately half of Caucasian LTNP, two host genotypes,
namely HLA-B57 and HLA-B27, are associated with viral control. Immunodominant CD8
T-cells from these individuals target epitopes in p24 that are highly conserved, and escape
mutations have significant fitness costs to the virus. Furthermore, recent studies have sug-
gested that these CD8 T-cells from LTNP, but not from HLA-B27 or HLA-B57 progressors,
can cross-react with intermediate escape mutations, preventing full escape via compen-
satory mutations. Humoral immunity appears to play little part in LTNP subjects, since
broadly neutralizing antibodies are rare, even amongst slow progressors. Recent genome-
wide comparisons between LTNP and progressors have confirmed the HLA-B57, HLA-B27,
and delta32 CCR5 allelic associations, plus indicated a role for HLA-C/KIR interactions, but
have not revealed any new genotypes so far. Nevertheless, it is hoped that studying the
mechanisms of intracellular restriction factors, such as the recently identified SAMHD1,
will lead to a better understanding of non-progression.
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INTRODUCTION
Prior to the introduction of potent combination antiretroviral
therapy (cART), in developed countries, the median time from
seroconversion to AIDS-defining illness was 8–10 years (reviewed
in Pantaleo and Fauci, 1996). However, slowly patients were rec-
ognized who showed little or no clinical progression (Lifson
et al., 1991; Learmont et al., 1992), later termed long-term non-
progressors (LTNP) (Pantaleo and Fauci, 1996). Recent data from
prospective cohorts suggest that only a very small minority of
untreated patients are LTNP and even fewer are able to sponta-
neously control HIV-1 replication, with undetectable plasma viral
loads and very stable CD4 cell counts (Madec et al., 2005; Goujard
et al., 2009; Okulicz et al., 2009; Mandalia et al., 2012); such patients
are commonly referred to as Elite Controllers (EC) (Blankson et al.,
2007; Walker, 2007).
VIRAL FITNESS IN LTNP AND EC
One of the earliest studies in non-progression was identification
of the Sydney Blood Bank Cohort (SBBC), where all subjects were
infected via blood transfusions from a single donor, who was an
LTNP himself (Learmont et al., 1992). It was found by full HIV-1
genome sequencing that the SBBC patients had been infected by
a highly attenuated nef/LTR deleted mutant strain (Deacon et al.,
1995). However, extensive analyses of viral isolates from other
cohorts of EC have found that such patients are rarely infected
with similar nef-deleted attenuated strains of HIV-1 (Miura et al.,
2008; Pushker et al., 2010). Instead, many LTNP and EC can have
fully replication competent HIV-1 (Alexander et al., 2000; Blank-
son et al., 2007; Lamine et al., 2007), although, more detailed
studies suggest that there can be subtle decreases in function of
Nef (Mwimanzi et al., 2013) or rare polymorphisms and reduced
function in other genes (Alexander et al., 2000; Miura et al., 2010).
In addition, env genes from EC subjects appear to be subtly differ-
ent to chronic progressors, with reduced rates of entry into cells
at defined levels of cell surface CD4 and CCR5 expression (Lassen
et al., 2009). In some cases, transmitted drug resistant HIV-1 may
have an associated fitness cost and result in lower viral load in the
recipient (Harrison et al., 2010).
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Therefore, there is evidence that in some LTNP and EC individ-
uals, infection with HIV-1 exhibiting low viral replicative fitness
may help explain viral control. However, it is also possible that in
many LTNP and EC, other immunological factors such as pressure
exerted by their CD8 cytotoxic T lymphocytes (CTL) upon viral
sequences vital to replication, has led to mutations that reduce viral
fitness (reviewed in Goulder and Watkins, 2004). Studies of exper-
imental SIV infection (Allen et al., 2000; O’Connor et al., 2002)
and recent studies of primary HIV-1 infection (PHI) demon-
strate that CTL escape mutations occur very early after infection
(Goonetilleke et al., 2009; Miura et al., 2010; Henn et al., 2012).
In retrospective studies of LTNP and EC who are defined after
many years of infection, it may be difficult to determine which
came first, infection with low replicative fitness HIV-1, or immune
pressure leading to unfit escape mutants, as discussed in detail
below.
A proportion of subjects who are initially viral controllers after
PHI exhibit viral breakthrough, suggesting that many factors are
involved in prolonged EC status (Madec et al., 2005; Goujard et al.,
2009; Okulicz et al., 2009). In the case of the SBBC subjects, three
out of four who had low but detectable viral loads, eventually had
further mutations that resulted in less attenuated HIV-1 and dis-
ease progression after 14–18 years (Gorry et al., 2007; Zaunders
et al., 2011). Similarly, HLA-B27 LTNP with low viral loads can
exhibit step-wise mutations leading to compensation and a rel-
atively high replication escape mutant strain of HIV-1 (Kelleher
et al., 2001) associated with clinical progression (Goulder et al.,
1997; Ammaranond et al., 2011).
VIRAL LOAD IN LTNP AND EC
Following the introduction of plasma HIV-1 RNA viral load mea-
surement by PCR, it was found that HIV+ patients exhibited a
very broad spectrum of viral load, from low to high levels, over
six orders of magnitude, and that a longer time to AIDS-defining
illness was highly correlated with lower viral load (Mellors et al.,
1997). LTNP have significantly lower plasma HIV RNA viral loads
than progressors (Panteleo et al., 1995), and by definition EC sub-
jects have undetectable plasma viral load. The level of HIV RNA
plasma is believed to reflect ongoing high levels of viral replica-
tion, particularly in lymphoid tissues, since virions in plasma are
reportedly produced and cleared very rapidly, with a half-life of
the order of 0.5–2 h (Ramratnam et al., 1999). Therefore, LTNP
and EC have greatly reduced viral replication in tissues.
In addition to HIV RNA in plasma, the levels of HIV DNA
in PBMC have also been measured by quantitative PCR, and
in general the two parameters are highly correlated (Rouzioux
et al., 2005), although the observed range of HIV DNA levels only
encompasses three orders of magnitude. Again, a lower level of
HIV DNA in PBMC is correlated with delayed clinical progres-
sion to AIDS (Rouzioux et al., 2005). Accordingly, LTNP and EC
have been found to have significantly lower levels of HIV DNA
in PBMC, compared to other patients (Panteleo et al., 1995; Lam-
botte et al., 2005; Dalmasso et al., 2008; Julg et al., 2010a; Graf et al.,
2011; Zaunders et al., 2011; Mendoza et al., 2012a). This low level
of HIV DNA is consistent with early studies showing that it was
relatively difficult to isolate HIV-1 from plasma or PBMC from
such patients, for example in the SBBC (Learmont et al., 1992;
Deacon et al., 1995), and also in later studies using highly sensitive
co-culture methods (Blankson et al., 2007).
Since HIV-1 dissemination throughout the lymphoid system
occurs shortly after infection, the question arises whether it is crit-
ical events during PHI that determine the reduced viral burden
in LTNP/EC. These considerations indicate that the formation of
the reservoir of HIV DNA within infected cells is different for
LTNP and EC subjects during PHI, resulting in overall reduced
viral burden.
Viral replication is at its highest during the very early stages
of PHI (Clark et al., 1991), then decreases to an apparent long-
term equilibrium, that is referred to as the set point (Mellors
et al., 1995). The peak of viral load, the subsequent kinetics of the
decrease, and the set point are all quite different for each individual
patient (Kaufmann et al., 1998), strongly suggesting that LTNP or
EC status could be established at this time. During this period of
high viral load, a considerable number of memory CD4+ T-cells
are infected with proviral HIV DNA that integrates into genomic
DNA, to form the cellular basis of the HIV-1 reservoir that is resis-
tant to cART (Chun et al., 1998). The reservoir formed during
PHI may possibly be slightly less long-lived (Chun et al., 2007)
and slightly smaller than the reservoir established by the time of
1 year of chronic infection (Strain et al., 2005; Koelsch et al., 2011).
Primary HIV-1 infection is a period when a vigorous immune
response to HIV-1 antigens occurs, with appearance of antibodies
(Cooper et al., 1985), as well as a dramatic increase in activated
CD4 and CD8 T-cells (Zaunders et al., 1995). It is generally
believed, from experimental SIV infection in Rhesus macaques,
that the initial focus of infection occurs in resting CD4 T-cells in
genital mucosa, followed very shortly by spread to lymphatic tis-
sues (Haase, 2010). Dissemination and formation of the reservoir
is believed to be fueled by inflammation and infection of respond-
ing activated CD4 T-cells (Haase, 2010), and it has been proposed
that some of these activated cells revert to long-lived resting mem-
ory T-cells containing replication competent provirus (Han et al.,
2007). We have found that much of the HIV DNA in PBMC during
the most acute stage of PHI was already found in long-lived resting
CD4 memory T-cells that expressed the IL-7 receptor (Zaunders
et al., 2006b), rather than the highly activated short-term effector
CD4 T-cells that peak during PHI (Zaunders et al., 2005). At the
peak of PHI, it is unlikely that activated cells have already reverted
to resting cells. Also, it is widely believed that most HIV-specific
CD4 T-cells, which should represent the bulk of activated CD4
T-cells during PHI, are lost, presumably due to infection, unless
patients commence cART (Rosenberg et al., 1997), consistent with
the report that HIV-specific CD4 T-cells are preferentially infected
with HIV DNA (Douek et al., 2002).
Altogether, the very low levels of HIV-specific CD4 T-cells after
PHI suggest that it is unlikely that they represent the majority
of the long-lived resting memory CD4 T-cell reservoir for provi-
ral HIV, as suggested by the infected activated cells reverting to
resting cells model. Rather, direct infection of long-lived resting
IL-7R+CD4 T-cells, while they transit through infected lymphoid
tissue, may be more likely to result in the cART-resistant reservoir,
and that IL-7 maintains homeostasis of these memory CD4 T-
cells (Chomont et al., 2009). The antigen specificity of the HIV
DNA-infected memory CD4 T-cell reservoir is unclear at present.
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The issue becomes whether PHI is different for LTNP or EC,
and whether their outcome is lower HIV RNA and HIV DNA
viral load due to reduced replication and dissemination, com-
pared to other patients. Approximately half of EC are HLA-B57
(Migueles et al., 2000) (see below) and an early report concluded
that HLA-B57 individuals presented significantly less often with
symptomatic PHI, suggestive of a milder course of disease (Alt-
feld et al., 2003). Furthermore, six out nine of the HLA-B57 PHI
subjects in that study had relatively low plasma viral loads (Altfeld
et al., 2003). However, in another prospective study of PHI, eight
EC were identified amongst 211 untreated PHI subjects (out of a
total of 964 subjects enrolled), and there was no significant differ-
ence in symptomatic PHI (Goujard et al., 2009), but there was a
clearly significant difference in HIV RNA viral load. Similarly, we
found that patients who exhibited better control of HIV RNA, dur-
ing treatment interruption after 6–12 months cART commenced
during PHI, had a significantly lower HIV RNA level at baseline,
by multivariate analysis (Bloch et al., 2006), and this correlated
with lower levels of integrated HIV DNA prior to cART (Lewin
et al., 2008). Another large natural history study showed that viral
control was established in the majority of EC within 1 year of sero-
conversion, but characteristics of PHI were not reported for this
cohort (Okulicz et al., 2009). However, within this same group of
patients, lower HIV DNA levels in purified CD4 T-cells at baseline
correlated with longer time to clinical progression (Ganesan et al.,
2010).
Altogether, there is consistent evidence indicating that
LTNP/EC emerge from PHI with low levels of chronic HIV-1 repli-
cation, and possibly low levels of long-lived memory CD4 T-cells
infected with HIV-1 DNA, but the rarity of these patients to study
during PHI makes it difficult to power studies for greater statistical
significance.
ARE CD4 T-CELLS FROM LTNP AND EC RESISTANT TO HIV-1
INFECTION?
If LTNP and EC have lower peaks of viral load during PHI
and lower viral set points after PHI, the possibility arises that
their CD4 T-cells are simply more difficult to productively infect
with HIV-1.
At the time of the discovery that CCR5 was the major co-
receptor for HIV-1 on the surface of CD4 T-cells, studies showed
that subjects heterozygous for the CCR5∆32 mutation had lower
plasma viral loads, slower declines in CD4 T-cell counts, and
delayed progression (Dean et al., 1996; Huang et al., 1996). An
increased prevalence of heterozygosity for the CCR5 ∆32 muta-
tion was found in some well-defined cohorts of LTNP (Morawetz
et al., 1997; Stewart et al., 1997), but not all, although a meta-
analysis of many cohorts confirmed that this genotype had a strong
protective effect delaying progression to AIDS-defining illness
(Ioannidis et al., 2001). This heterozygosity was believed to reduce
cell surface CCR5 by a dominant negative effect of the∆32 mutant
allele (Benkirane et al., 1997), presumably limiting HIV-1 entry,
although the effect on cell surface CCR5 is quite variable for indi-
vidual ∆32 heterozygous subjects (de Roda Husman et al., 1999).
The prevalence of∆32 heterozygosity in EC appears be statistically
higher than in the general population (Pereyra et al., 2010), but
not dramatically so, and where reported, the large majority of EC
are wild-type for the CCR5 allele (Lambotte et al., 2005; Pereyra
et al., 2008).
Since Env from EC isolates required more CCR5 and CD4 for
entry than env from chronic progressors (Lassen et al., 2009), this
suggested the possibility that subtle changes in both env and CCR5
expression in the same patient could together contribute signifi-
cantly to viral control. Also, the ∆32 mutation, plus two other
previously described SNP’s in the CCR5-CCR2 locus, were the
only polymorphisms other than HLA alleles that were significant
in a genome-wide genetic association study of viral controllers,
compared to progressors (Pereyra et al., 2010).
Direct study of the ability of HIV-1 to infect CD4 T-cells from
EC has yielded conflicting results. Most reports have found that
CD4 T-cells from EC can be infected with autologous or labora-
tory strains of HIV-1, using activated CD4 T-cells (Wang et al.,
2002; Blankson et al., 2007; Lamine et al., 2007; Julg et al., 2010a)
or resting CD4 T-cells (O’Connell et al., 2011; Rabi et al., 2011).
However, one study recently reported that CD4 T-cells from EC
were relatively resistant to HIV infection in vitro, describing a
role for the tumor suppressor, p21Cip1/Waf1, although a mecha-
nism for the effect of reduced reverse transcription was unclear
(Chen et al., 2011). A second report found that macrophages
from EC have low susceptibility to HIV-1 infection, while CD4
T-cells from the same patients, had reduced reverse transcrip-
tion in the first round of infection, similar to the first report,
although no direct role for p21 could be found (Saez-Cirion et al.,
2011).
Interestingly, CD4 T-cells in PBMC from EC had very low lev-
els of integrated HIV DNA, but relatively high levels of episomal
2-LTR circles (Graf et al., 2011). The authors did not find a block
to integration, but rather concluded that in these patients, CD8
CTL pressure possibly rapidly removed infected cells, leaving a
proportionately higher population of non-productively infected
cells (Graf et al., 2011).
A potential problem with directly comparing CD4 T-cells from
EC to CD4 T-cells from progressors is the effect of chronic HIV-1
infection associated with increased rates of activation. We origi-
nally found that EC subjects in the SBBC had much lower levels
of activation (within the normal range), and greatly increased
numbers of resting memory CD4 T-cells, compared to progressors
(Zaunders et al., 1999b). This was reported again in a later study
of EC (Potter et al., 2007), and has since been also suggested in
another study of EC, although not explicitly reported (Hunt et al.,
2008). In this latter study, activation was barely elevated, partic-
ularly in EC with CD4 cell counts ≥600 cells/mm3, compared to
HIV-uninfected controls (Hunt et al., 2008), meaning that EC had
greatly increased resting cells compared to progressors.
The HIV-1 restriction factor SAMHD1 is an interferon
inducible enzyme in myeloid cells (Goldstone et al., 2011; Hrecka
et al., 2011) which limits HIV-1 infection through depleting avail-
able dNTP for reverse transcription (Lahouassa et al., 2012).
Identified using mass-spectrometry as a counteracted target for
the HIV-2/SIV protein Vpx (Laguette et al., 2011), SAMHD1
highlights the role of intrinsic host factors in limiting reservoir
generation particularly in resting CD4 T cells. Polymorphisms in
the SAMHD1 gene currently demonstrate no strong associations
with non-progressive status (Coon et al., 2012), however it is clear
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that the role of SAMHD1 as an intrinsic factor associated with EC
has not been thoroughly investigated.
Another restriction factor, TRIM5a, has been studied for poten-
tial polymorphisms in LTNP, although this restriction factor is
much more active against SIV in human cells than it is against
HIV-1 (Nakayama and Shioda, 2012). One study reported that a
H43Y mutation in TRIM5a was associated with accelerated pro-
gression (van Manen et al., 2008), although this was not confirmed
in other studies (Nakayama and Shioda, 2012).
Altogether there is not clear-cut evidence that EC have CD4
T-cells that are resistant to HIV-1 infection. Direct comparisons
of PBMC from LTNP/EC versus progressors must be critically
assessed to take into account possible differences in the relative
proportions of resting and activated CD4 T-cells, since resting
cells are known to be harder to infect in vitro (Zack et al., 1990).
DO LTNP AND EC HAVE A MORE VIGOROUS IMMUNE
RESPONSE TO HIV-1 ANTIGENS DURING PHI?
An effective CD8 T-cell response is believed to be important in
reducing the peak of viral load after PHI (McMichael et al., 2010),
and the association of such responses with LTNP and EC status is
discussed below.
However, there is also a significant CD4 T-cell response to HIV
infection as well during PHI (Rosenberg et al., 2000; Oxenius et al.,
2001; Gloster et al., 2004; Kaufmann et al., 2004; Zaunders et al.,
2005; Maenetje et al., 2010; Riou et al., 2012). We have consistently
found that there is a transient, greatly increased rate of activa-
tion and proliferation of CD4 T-cells which results in high levels
of CD38high, CCR5+, Ki67+, and CD127low cells (Zaunders
et al., 1995, 2001, 2005), making ideal targets for highly productive
HIV-1 infection. A similar population of activated CD4 T-cells
is observed from day 10 to day 14 following vaccinia inoculation
in healthy adult volunteers (Zaunders et al., 2006a). It may be
counter-intuitive, but a relatively restrained CD4 T-cell response
could be beneficial if fewer activated cells are generated during
PHI. Rather than resistance of CD4 T-cells to infection, a reduced
immune response and lower number of target cells generated for
productive infection during PHI may play an important part in
LTNP/EC status. Consistent with this possibility, a recent study of
a large natural history cohort showed that a lower proportion of
such activated CD4 T-cells at baseline was highly correlated with
lower cell associated HIV DNA levels (Ganesan et al., 2010), lower
plasma viral loads (Okulicz et al., 2009), and better long-term
outcome (Ganesan et al., 2010).
The role of an anti-HIV-1 CD4 T-cell response in simul-
taneously controlling HIV-1 replication, but at the same time
contributing target cells, is obviously complex.
There are numerous reports of the deleterious effect of high
HIV-1 viral replication in patients on their CD4 T-cell function
in vitro and in vivo, including: (i) reduced IL-2 production (Clerici
et al., 1989), and we have found recently this is associated with
over-expression of the transcriptional repressor Blimp-1 in CD4
T-cells from progressors, compared to LTNP (Seddiki et al., 2012);
(ii) reduced proliferation in response to standard mitogens and
antigens (Miedema et al., 1988; Clerici et al., 1989), including
response to HIV antigens (McNeil et al., 2001), probably secondary
to reduced IL-2 production; (iii) increased CTLA-4 expression,
which is a known negative regulator of CD4 T function (Zaun-
ders et al., 2006b; Kaufmann et al., 2007); (iv) increased PD-1
expression (Day et al., 2006), although the exact mechanism of
negative function is not defined, but may be linked to increased
IL-10 production (Brockman et al., 2009; Said et al., 2010) and
the transcription factor BATF (Quigley et al., 2010); (v) fibrosis of
lymph nodes, possibly leading to reduced availability of IL-7 medi-
ated survival signals (Estes et al., 2008), combined with reduced
proportions of IL-7R+ CD4 T-cells possibly due both to activa-
tion and to reduced homeostasis (Sasson et al., 2006). It is very
important to note, however, that treating patients with subcuta-
neous IL-2 in a series of very large clinical trials did not lead to any
clinical benefit (Abrams et al., 2009).
In contrast, LTNP and EC subjects are best distinguished by the
observation that CD4 T-cells in their PBMC proliferate in vitro
in response to HIV-1 antigens, described in numerous reports
(reviewed in detail in Dyer et al., 2008). These results strongly sug-
gest that LTNP and EC subjects have a significant population of
circulating HIV-specific memory CD4 T-cells. Furthermore, CD4
T-cells from EC subjects responded to, on average, 10-fold lower
concentrations of Gag peptides in vitro than corresponding cells in
other HIV+ subjects, suggesting that the HIV-specific CD4 T-cells
from EC had much higher avidity TCR (Vingert et al., 2010).
These CD4 T-cells may have an indirect effect by helping a
potent CD8 response to control HIV replication (Kalams and
Walker, 1998), and while it is still unclear how this may occur,
production of IL-2 has been implicated (Lichterfeld et al., 2004)
and more recently IL-21 (Yue et al., 2010; Chevalier et al., 2011;
Williams et al., 2011), although improved CD8 function may be
also maintained by autochthonous production of IL-2 (Zimmerli
et al., 2005) or IL-21 (Williams et al., 2011).
Another possibility however, is a direct anti-viral effector func-
tion of HIV-specific CD4 T-cells. We found that one individual
LTNP, who had an extremely low rate of HIV-1 replication (Wang
et al., 2002), had a very vigorous CD4 proliferation in response to
HIV-1 Gag, and when these cells were identified as an expansion
of TCR Vβ17+ cells, it allowed detailed study of their pheno-
type to be performed (Zaunders et al., 2004). It was found that
these Vβ17+ CD4+ T-cells had a cytotoxic phenotype (shown in
Figure 1) and were able to lyse autologous B cells coated with the
cognate peptide (Zaunders et al., 2004). Another study in parallel
similarly found that an LTNP with a very large proliferative CD4
response also had cytotoxic CD4 T-cells specific for a Gag peptide
(Norris et al., 2004). In both cases, the epitope overlapped with
a CD8 immunodominant epitope recognized by CD8 CTL from
HLA-B57 LTNP and EC (see below). Furthermore, the same epi-
tope was significantly more commonly recognized by CD4 T-cells
from EC subjects, and resulted in greater proliferation in vitro,
than for CD4 T-cells from other HIV+ subjects (Vingert et al.,
2010).
We had previously found that HIV-1 infection was associated
with an increase in circulating CD4+ T-cells that contained per-
forin (Appay et al., 2002). These perforin+ CD4 T-cells could
be seen even as early as during PHI (Appay et al., 2002) and we
subsequently found that HIV-specific CD4 T-cells during PHI
highly expressed markers of CTL (Zaunders et al., 2005). These
results suggest that CD4 effector cells with a CTL phenotype are a
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FIGURE 1 | LTNP 100149 CD4 response to HIV-1 p24. Flow cytometry
histograms showing that (A) subject LTNP 100149 cells had a very large CD4
response [(A), upper row of histograms] to HIV p24 (baculovirus recombinant)
and also to Gag 15-mer peptide SPEVIPMFSALSEGA (peptide #42 from NIH
reagents program). LTNP 100149 had an expansion of TCR Vβ17 CD4 T cells
[(A), middle row] that had half the original response to p24 and all the original
response to peptide #42, while CD4 T cells excluding TCR Vβ17 cells [(A),
lower row] had half the original response to p24, but no response to peptide
#42. (B) Immunophenotyping of LTNP100149 TCR Vβ17+ CD4 T cells [(B),
upper row] showed that they had very high expression of the cytotoxic
granule marker TIA-1, dim CCR5, Granzyme A, and CD127 (IL-7Rα chain),
relative to CD4 T cells excluding TCR Vβ17 cells [(B), lower row].
surprisingly common component of an anti-viral response, which
we confirmed by detailed study of the primary immune response
during the first 3 weeks after vaccinia inoculation in healthy adults
(Zaunders et al., 2006a). Similarly, in many individuals, CMV-
specific CD4 T-cells can have a cytotoxic phenotype (Gamadia
et al., 2004; Zaunders et al., 2004; Casazza et al., 2006), including
during primary CMV infection (Gamadia et al., 2004). The results
described above suggest that they can contribute significantly to
viral control in rare HIV+ patients. A recent report of 11 subjects
studied during PHI suggested that a higher level of Granzyme A+
HIV-specific CD4 T-cells during PHI correlated with a slower rate
of progression and better clinical outcome (Soghoian et al., 2012).
Evidence from SIV infected EC monkeys has also suggested that
there are CD4 CTL that control SIV replication in vivo (Sacha
et al., 2009; Burwitz et al., 2012). The role of CD4 CTL has not
been studied to same extent as CD8 CTL, but is gaining greater
appreciation in other viral infections (Sant and McMichael, 2012).
Interestingly, another study has reported that lower viral loads
in LTNP were associated with CD4 responses skewed toward Gag
epitopes, while progressor subjects had responses skewed toward
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Env epitopes (Ranasinghe et al., 2012). This is highly reminiscent
of an earlier corresponding result in CD8 responses (Kiepiela et al.,
2007), discussed below. HLA-DRB1∗13 presents another epitope
that is from a highly conserved section of HIV Gag, and it was
found that subjects treated during PHI who were HLA-DRB1∗13
and had responses to this epitope, had a better clinical response to
therapy (Malhotra et al., 2001). Another study has confirmed that
subjects with HLA-DRB1∗13 did better in HIV clade C infection
(Julg et al., 2011).
A possible explanation to reconcile all these observations may
be that LTNP have reduced CCR5 expression on a critical CD4
effector subset, especially during PHI, making them less suscepti-
ble to infection and loss. Central memory CD4 T-cells (Tcm) are
believed to be a long-lived subset of CD4+ T-cells and are more
proliferative than effector memory CD4 T-cells (Tem) (Sallusto
et al., 2004). In a study of HLA-B27 and HLA-B57 LTNP, Tcm
contained particularly low levels of HIV DNA, which was asso-
ciated with lower levels of cell surface CCR5 expression on Tcm
(Descours et al., 2012). Consistent with these results, another study
has very recently been presented at CROI 2013, that found that EC
had lower levels of CCR5 on activated Tcm (Ramirez Kitchen et al.,
2013).
Altogether, there is not clear-cut evidence that EC have CD4
T-cells that are resistant to HIV-1 infection. Rather than EC hav-
ing a greater magnitude immune response to HIV-1, they may
have a less broad response that is more focused on critical Gag
epitopes, which may include cytotoxic CD4 T-cells and in which
activated HIV-specific CD4 Tcm cells may have lower levels of
CCR5 expression. Conversely, progressors with higher viral loads,
associated with continual generation of diverse quasispecies in Env
sequences, may maintain higher levels of activated CCR5+ CD4
T-cells, beginning during PHI (Zaunders et al., 2001, 2005) and
continuing during chronic infection. If these cells tend to respond
vigorously to Env epitopes, this may increase target cell numbers
and contribute to continuing higher viral load, more dysregulated
CD4 homeostasis and greater decline in the number of resting
CD4 T-cells.
HLA ASSOCIATIONS WITH HLA-B57 AND HLA-B27, AND CD8
T-CELL CONTROL OF VIRAL REPLICATION IN LTNP AND EC
Patients classified as non-progressors are overrepresented by indi-
viduals with alleles from the HLA-Bw4 serotype, namely HLA-
B∗2705, which is overrepresented in Caucasian LTNP cohorts
and HLA-B∗5701 and HLA-B∗5703, from Caucasian and African
cohorts, respectively (Carrington and O’Brien, 2003). The multi-
national HIV Controllers Study completed a genome-wide asso-
ciation study to determine any association of immunogenetics
with viral control across multiple ethnicities (Pereyra et al., 2010).
While>300 SNP associations were identified (all within the MHC
complex), non-progression for European individuals exclusively
fell in order of an odds-ratio for delayed progression within
the HLA alleles; HLA-B∗5701/B∗5201, HLA-B∗2705, and HLA-
B∗1402 (Pereyra et al., 2010). In particular, roughly half of EC are
HLA-B57 as originally reported by Migueles et al. (2000).
These alleles are capable of mounting effector CD8+ T-cell
responses that target several parts of HIV-1 (Goulder et al.,
1996, 1997, 2001a). In the majority of cases however, these
patients mount a narrowed but highly effective immunodominant
response to the p24 capsid protein of HIV Gag.
The capsid protein consists of two helical domains; the C-
terminal domain (residues 148–231) which is critical for Gag
dimerization and is highly conserved among retroviruses. The N-
terminal domain (residues 1–146) functions in maturation of the
virus and correct viral disassembly following viral entry. The HLA-
B∗2705 target epitope KRWIILGLNK (KK10) lies along helix 7,
while importantly, the B∗5701 epitopes KAFSPEVIMF (KF11) and
TSTLQEQIGW (TW10) lie along the respective helices 2 and 6.
Targeting of these epitopes, which are critical to viral function,
strongly suggests the active selection of an attenuated virus in
order to escape from CD8+ T-cell surveillance. Mutations at these
epitopes are a casus fortuitus, an “unavoidable accident” of nature
that are required to allow immune escape, but come at a high price,
resulting in significant loss of fitness (Goulder and Watkins, 2004).
The definitive example of viral immune escape occurs in indi-
viduals expressing HLA-B∗2705, in which a series of concurrent
mutations takes place during the course of infection, in the KK10
epitope. An initial mutation at position 6 from Leu to Met (L268M)
early in infection (Lichterfeld et al., 2007), is considered an attempt
to escape T-cell receptor recognition. Studies suggest an antago-
nistic effect from this change (Klenerman et al., 1994), despite no
difference observed in peptide binding affinity to the MHC class
I molecule (Ammaranond et al., 2003). This mutation is tightly
clustered with a second Arg (R) to Lys (K) mutation at position
2 (R264K) (Kelleher et al., 2001), which is a prerequisite residue
for binding to the HLA-B∗2705 molecule. The R264K mutation
is always observed with a simultaneous upstream compensatory
Serine to Alanine (S173A) mutation, required for independence
of host cyclophilin-A for post-entry uncoating (Schneidewind
et al., 2007). MHC binding affinity is then significantly reduced
and capacity for presentation of this epitope is lost. Importantly,
the timing of the R264 mutation is commonly observed no ear-
lier than 8–10 years following infection, demonstrating the critical
importance of viral fitness to clinical outcome.
Perinatal transmission of an existing R264K mutation results in
the incapacity to mount an equivalent immunodominant response
(MacDonald et al., 1998; Goulder et al., 2001b); however mecha-
nistically, this differs from transmission of the T242N TCR escape
mutation generated from the immunodominant HLA-B∗5701
(TW10) epitope (Schneidewind et al., 2009; Miura et al., 2010).
In a dissimilar fashion to R264K, haplo-identical infants are able
to maintain fitness-attenuated virus through p24 Gag (Goulder
et al., 2001b). The impact of HLA-B∗5701 is thus apparent from
the onset of infection and, among other factors, may contribute
to a reduced viral reservoir. Ultimately, it is a combination of viral
and host factors which contribute to disease progression in these
individuals (Norstrom et al., 2012).
CD8 EFFECTOR FUNCTION IN LTNP AND EC
The classic CD8 effector function is cytotoxic activity toward
infected target cells. Knockout of perforin in murine mod-
els yields a very clear phenotype in which control over non-
cytopathic viral infections is lost, whereas control over cytopathic
viruses is more dependent on antibodies and interferon gamma
(Kagi and Hengartner, 1996). Whether HIV-1 by itself is directly
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cytopathic for CD4 T-cells in vivo is unclear. This is an extremely
important consideration, since lysis of infected cells is doubly
important in HIV infection due to the ability of the virus to
integrate and remain dormant in long-lived cells (Han et al.,
2007). Therefore CD8 lysis of HIV-infected CD4 T-cells may be
required to simultaneously reduce viral replication and provi-
ral HIV DNA burden. Certainly, syncytium-inducing strains of
HIV-1 are clearly directly cytopathic, but they are generally not
found in early HIV-1 infection (Richman and Bozzette, 1994),
so that CD8 control of non-syncytium-inducing strains during
PHI is extremely important. In fact, it is widely believed that CD8
cytotoxicity is the main immune mechanism to control HIV infec-
tion (reviewed in detail in McMichael, 1998; McMichael et al.,
2010).
Nevertheless, some early studies suggested that CD8 T-cells
from LTNP had a non-cytotoxic, soluble factor-mediated suppres-
sive activity, reducing HIV-1 replication in vitro (Walker et al.,
1986; Yang et al., 1997; Barker et al., 1998; Wilkinson et al.,
1999) as well as more recent studies suggesting significant sup-
pression of HIV replication in autologous CD4 T-cells in vitro
(Julg et al., 2010b). However, a lack of any mechanism eluci-
dated for this suppression, particularly definition of any soluble
mediator responsible (Levy, 2003) has seriously called this sup-
pression into question. Furthermore, a recent study of EC clearly
found that CD8 T-cells required contact with infected CD4 T-cells
to reduce HIV replication, indicating cytotoxicity was the main
mechanism (Saez-Cirion et al., 2007). Consistent with the role
of cytotoxicity, an earlier study of HLA-B57 LTNP had shown
that their HIV Gag-specific CD8 T-cells responded to antigen
by proliferation and up-regulation of perforin (Migueles et al.,
2002).
However, CD8 T-cells in LTNP may have more functions
than just cytotoxicity. Betts et al. (2006) conducted a qualita-
tive study to identify immunological correlates of disease protec-
tion, describing polyfunctionality as an important characteristic
of CD8+ T-cell control that was inversely related to viral load
in LTNP. Polychromatic flow cytometry was used to simultane-
ously assess five functional responses of antigen-specific CD8+
T-cells; production of TNFa, IL-2, IFNg,MIP1b,and up-regulation
of CD107a (degranulation). LTNP displayed an enhanced func-
tional profile of four or five simultaneous functions (Betts et al.,
2006), also confirmed in HLA-B27 LTNP (Almeida et al., 2007,
2009).
Importantly, as for CD4 responses described above, a large
study of HIV+ subjects in South Africa showed a clear associa-
tion of lower viral loads with CD8 T-cell responses to Gag, while
responses to Env were associated with higher viral loads (Kiepiela
et al., 2007). It is presumed that a major reason is probably that
escape mutations in Gag are highly constrained by their effect on
fitness (Goulder and Watkins, 2004), as discussed above for HLA-
B27 LTNP and their very gradual loss of control. In addition, it
has been suggested that epitopes from Gag could be presented
very early after viral entry into the target cell and before integra-
tion and productive infection (Sacha et al., 2007). As mentioned
above, this could be doubly important in preventing establishment
of the latent reservoir of HIV DNA infected long-lived memory
CD4 T-cells, as observed in LTNP (Descours et al., 2012).
CD8 TCR FUNCTIONAL AVIDITY AND LTNP
Increased antigen sensitivity represents the efficiency of CD8+
T-cells to expand and respond to lower levels of antigens during
infection; while potentially providing an advantage to controlling
infection, this feature may also leave cells prone to exhaustion
(Almeida et al., 2007; Lichterfeld et al., 2007). Also referred to as
functional avidity, assessment is quantifiable (normally through
EC50 of antigen titration), by measurement of function down-
stream of TCR signaling, such as proliferation and cytotoxicity.
So, the question arises whether LTNP have CD8 T-cells that are
highly sensitive to antigen and more effective at clearing infection.
Recruitment of T-cells with high avidity has been demon-
strated to occur during early HIV infection and is associated with
a decline in viremia (Lichterfeld et al., 2007). Study of CD8 T-
cells from HLA-B27 HIV+ subjects showed that those individuals
with CD8 T-cells that responded to lower antigen concentration,
i.e., higher functional avidity, had the lowest HIV DNA in PBMC
(Almeida et al., 2007) and plasma viral load (Almeida et al., 2009).
High avidity CD8 T-cells were also much more effective in sup-
pressing HIV-1 replication in vitro (Almeida et al., 2009; Bennett
et al., 2010). However, some progressing HIV+ subjects may also
have CD8 T-cells with apparent high avidity to autologous HIV-1,
as measured by IFNg responses in vitro (Draenert et al., 2004),
although polyfunctionality was not studied. Similarly, protective
effects may also be associated with low to medium-avidity CD8 T-
cells (Harari et al., 2007). Furthermore, high avidity CD8 T-cells
appear to express higher levels of the dysfunction marker PD-1
(Harari et al., 2007), and the senescence marker CD57 (Almeida
et al., 2007), and may be subject to higher rates of apoptosis
(Vigano et al., 2012).
Therefore, it appears that high functional avidity CD8 T-cells
per se do not necessarily lead to LTNP status, that other factors
controlling longevity of these CD8 T-cells may also be important.
CD8 IMMUNODOMINANCE AND CLONAL TURNOVER AND
LTNP
The evidence from HLA-B27 and HLA-B57 LTNP and EC sug-
gests that efficient, immunodominant CD8+ T-cells responses
maintain control over viral replication, but it is not known how
this dominance is established, maintained, and linked with non-
progression. Logically, cells that have the capacity to rapidly
expand in vivo to limiting amounts of antigen have a compet-
itive advantage and would predominate when confronted with
the task of clearing pathogen. Recruitment of clonotypes making
up the immunodominant response to the HLA-B∗2705-restricted
KK10 epitope is closely linked to viral replication. Treatment-
naïve non-progressors recruited multi-functional KK10-specific
CD8+ T-cells that were prone to replicative senescence follow-
ing up-regulation of the marker CD57 (Almeida et al., 2007).
However, a similar longitudinal study of the KK10 response noted
the persistence of immunodominant clonotypes, which expressed
markers of long-lived CD8 T-cells, namely high IL-7R and Bcl-
2 (van Bockel et al., 2011). A notable feature of these long-lived
immunodominant clones in the latter study was their ability to
bind to tetramers containing the wild-type peptide, as well as to
tetramers containing the mutant L268M peptide (van Bockel et al.,
2011) as shown in Figure 2, and discussed below.
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The factors controlling recruitment of clones and immun-
odominance are not well understood. New clonal responses can be
recruited during chronic infection, a classic example being HLA-
A2 individuals who do not have CD8 T-cell responses to the p17
peptide SLYNTVATL during PHI, but response to this peptide
is immunodominant in 75% of HLA-A2 subjects with chronic
infection (Goulder et al., 2001a).
Extended control over replication by effective HLA-B27-
restricted CD8 T-cell clones may depend on their ability to respond
to closely related variants as they arise. Altogether, there may be a
complex dynamic of CD8 clonal recruitment in HLA-B27 subjects,
followed by pressure exerted by these cells on HIV-1, resulting
in appearance of variants in the epitope, which in turn affects
the differentiation state and longevity of the antigen-specific CD8
T-cells.
CROSS-REACTIVE TCR MAY PREVENT EFFECTIVE ESCAPE IN
HLA-B27
Considerable interest has recently focused upon cross-reactivity
of T-cells for viral epitope variants. Given the very large num-
bers of possible peptide epitopes that could be presented by the
MHC to T-cell receptors, it has been argued that a single TCR
may recognize multiple epitopes (Mason, 1998). These theoret-
ical considerations are supported by data in LTNP demonstrat-
ing TCR cross-reactivity by HLA-B∗2705-restricted KK10 clones
(Almeida et al., 2009; van Bockel et al., 2011; Chen et al., 2012) and
HLA-B∗5701/03-restricted clones (Gillespie et al., 2002; Turnbull
et al., 2006; Simons et al., 2008) toward known viral variants.
An example of an immunodominant clonotype that bound both
wild-type and L268M KK10 peptides is shown in Figure 2, as
originally described in van Bockel et al. (2011). A recent study
has reported that KK10-specific immunodominant CD8 clono-
types from HLA-B27 LTNP are extremely effective at suppressing
HIV-1 replication in vitro, with both wild-type KK10 and L268M
viral strains suppressed, whereas HLA-B27 progressors had CD8
clonotypes that were clearly inferior at suppressing wild-type and
did not suppress L268M strains at all (Chen et al., 2012). Sup-
pression by CD8 T-cells from LTNP compared to progressors was
most closely linked to rapid up-regulation of perforin (Chen et al.,
2012).
One report suggested that protective alleles such as HLA-B57
may have less deletion of relevant TCR clonotypes during negative
selection in the thymus, and therefore LTNP may have a greater
number of potential clonotypes to select from during PHI (Kosm-
rlj et al., 2010). However, another report studied the diversity of
HLA-B57-restricted anti-Gag clonotypes and found that LTNP
and progressors had similar numbers and diversity of clonotypes
(Mendoza et al., 2012b).
Therefore, the question of how LTNP have qualitatively supe-
rior CD8 T-cell responses remains unresolved, but their ability to
simultaneously suppress HIV-1 replication by both wild-type and
well characterized variants appears to be significant. Nevertheless,
one report suggests that one HLA-B57 LTNP, infected originally
with a nef-defective strain of HIV-1, was superinfected with a nef-
intact HIV strain despite having detectable HLA-B57-restricted
CD8 responses to the main HIV Gag epitopes (Braibant et al.,
2010).
FIGURE 2 | LTS12 CD8T cells binding toWT and L268M KK10
Tetramers. Flow cytometry histograms showing that subject LTS12 had a
very large CD8 T cell response to HLA-B27-restricted epitope KK10, both to
the wild-type sequence peptide-tetramer (lower histograms) and to the
L268M variant peptide-tetramer (upper histograms), over two time points
separated by 9 years. Clonotyping of sorted tetramer+ cells showed that
the dominant clonotypes were responding to both epitope sequences.
NK CELLS AND CONTROL OF HIV-1 INFECTION
NK cells typically represent 5–15% of circulating lymphocytes and
may be one of the first mechanisms in the defense against HIV-1
infection, prior to development of adaptive immune responses.
NK cells would be expected to lyse HIV-infected cells, since Nef
downregulates HLA class I molecules to reduce presentation of
antigens to cytotoxic CD8 T-cells (Collins et al., 1998), potentially
triggering NK cell cytotoxicity due to “missing self”(Alter and
Altfeld, 2009). However, Nef may selectively only downregulate
HLA-A and -B, leaving HLA-C and -E expression intact, thereby
also evading NK cells (Cohen et al., 1999). Loss of this function of
Nef may be important in the reduced fitness of Nef-deleted virus
in some LTNP, as described above. However, there are many other
reported functions of Nef (Foster and Garcia, 2008) and it must
be remembered that nef deletions overlap with 3′LTR (Gorry et al.,
2007).
Nevertheless, genetic evidence suggests that HIV+ subjects
with the activating KIR allele KIR3DS1, in combination with HLA-
B alleles that encode molecules with isoleucine at position 80
(HLA-B Bw4-80Ile), have delayed progression to AIDS (Martin
et al., 2002). It was subsequently found that this genetic combi-
nation resulted in NK cells from KIR3DS1+ subjects exhibiting
higher levels of degranulation toward HIV-infected Bw4 80I CD4
target cells and suppression of HIV-1 replication (Alter et al.,
2007).
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Furthermore, a genetic polymorphism located 35 kb upstream
of HLA-C has been found to be associated with slower HIV pro-
gression in genome-wide association studies (Fellay et al., 2007). It
was later found that this polymorphism was in strong linkage dis-
equilibrium with a variation within the 3′ untranslated region of
HLA-C that regulates binding of the microRNA species miR148a
resulting in relatively higher expression of HLA-C on the surface
of cells (Kulkarni et al., 2011). Therefore higher levels of HLA-
C, possibly related to NK cell activity, may be important for slow
progression.
Recently, there has been renewed interest in another function of
NK cells, namely antibody-dependent cell-mediated cytotoxicity
(ADCC), in which NK cells with the Fc receptor CD16 lyse target
cells that have antibody bound to antigens on their cell surface.
ADCC was originally believed to be one mechanism contribut-
ing to the reduction in plasma viral load after PHI (Koup et al.,
1994). Recently, ADCC responses to Env were correlated with slow
decline in CD4 T-cell count (Chung et al., 2011).
HUMORAL RESPONSES TO HIV
The antibody response to HIV-1 antigens begins around 1 week
after onset of symptoms and is absolutely characteristic of PHI
(Cooper et al., 1985; Tindall and Cooper, 1991). Antibodies to all
components of HIV-1 gradually appear and intensify on western
blot over several weeks (Tindall and Cooper, 1991). The observa-
tions that antibodies are predominantly class-switched IgG, that
there is evidence of somatic mutation from germ-line Ig genes, that
titers and affinity increase over time, and that there are numerous
germinal centers within lymph nodes, all point to a significant T
follicular helper (Tfh) CD4 cells-dependent antibody response to
HIV-1 infection (Crotty, 2011).
Very early treatment of PHI results in decreasing titers of anti-
p24 antibodies (Zaunders et al., 1999a) suggesting interruption
of this slow build up of antibodies. In fact, it is speculated that
decreasing antibody titers, which is rare even for EC subjects (Men-
doza et al., 2012a), may actually reflect a complete lack of viral
replication in tissues and decrease in available antigenic mater-
ial in germinal centers. In contrast, in progressive infection, the
amount of virions attached to the processes of follicular dendritic
cells is overwhelming (Haase, 1999) and outnumber all other viri-
ons in the body. Altogether, these results are not consistent with
the idea that HIV-specific CD4 T-cells are preferentially infected
and deleted during HIV infection (Douek et al., 2002). Instead,
very recent studies of Tfh in lymphoid tissue during SIV and HIV
infection have shown that these cells increase during chronic infec-
tion, even in progressive disease (Hong et al., 2012; Lindqvist et al.,
2012; Petrovas et al., 2012; Xu et al., 2013).
Therefore, the question arises whether LTNP and EC have a
more effective neutralizing antibody response than HIV+ subjects
with progressive infection. In studies of large numbers of sub-
jects with slow disease progression,broadly neutralizing antibodies
were uncommon, although some highly effective monoclonal anti-
bodies have been generated from selected patients (Zhou et al.,
2010; Walker et al., 2011). Overall, it is not believed that neutral-
izing antibodies play a major role in LTNP or EC status. However,
it remains possible that ADCC, mediated by NK cells, may play a
role in controlling HIV-1 replication in LTNP (Chung et al., 2011),
as mentioned above.
CONCLUSION
The predominant evidence suggests that LTNP and EC have effec-
tive CD4 and CD8 T-cell activities that in these rare cases are able
to target critical epitopes in HIV-1 Gag and severely limit HIV-1
infection and replication. The distinguishing feature of these cells
is their ability to rapidly proliferate, upregulate cytotoxic effector
molecules, lyse infected cells, and also respond to typical variants
that may arise.
While these insights have mainly come from LTNP and EC with
HLA-B57 and HLA-B27, approximately half of LTNP/EC subjects
do not have these alleles, and in some cohorts even lower pro-
portions have these alleles (Saez-Cirion et al., 2013). Therefore,
genome-wide genetic association studies were hoped to provide
further clues to LTNP and EC status, but only confirmed known
HLA associations (Pereyra et al., 2010).
With respect to CD4 and CD8 effector cells in LTNP/EC, it is
still difficult to definitively separate cause and effect, since they
may have characteristics of effector cells in a low viral load envi-
ronment. The observation that such effector cells, especially large
populations of proliferative Gag-specific CD4 T-cells, are not often
seen in subjects who had progressive infection and have suppres-
sive cART argues in favor of a causal relationship. A relatively
low viral load environment during PHI for LTNP/EC may be the
crucial difference.
How such responses can be generated therapeutically so that
HIV+ subjects can avoid lifelong ART remains a significant
challenge.
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